CD4 is a T-cell surface glycoprotein and serves as the receptor for the human immunodeficiency virus. Glycosylation of CD4 has been shown to be necessary for proper surface expression. To study the biosynthesis and assembly of CD4, wild-type and glycosylation-deficient mutant Chinese hamster ovary (CHO) cells were cotransfected with a cDNA encoding CD4 and a cDNA for the human multiple drug resistance gene, which allowed the amplification of the transfected CD4 cDNA sequences. Clones were isolated that exhibited high-level expression of CD4 resulting from the integration of several copies of CD4 cDNA. CD4 synthesized by these cells acquired resistance to endoglycosidase H after 20-30 min of chase, suggesting a rapid translocation ofthe glycoprotein from the rough endoplasmic reticulum to the medial Golgi apparatus. The sensitivity of CD4 to glycosidases suggested the presence of biantennary unsialylated complex-type oligosaccharides. Consistent with this, CD4 synthesized by the Lec2 mutant, which does not add sialic acid to oligosaccharides, was identical to the glycoprotein produced by wild-type CHO cells.
The amplification strategy used to express CD4 at high levels in wild-type and mutant CHO cells will have general utility.
We have shown (1) that inhibition of protein glycosylation by tunicamycin inhibited surface expression of CD4 in human acute lymphoblastic leukemia cells (CEM-CM3). We hypothesized that selective degradation of CD4 occurred when glycosylation was inhibited. Examining CD4 assembly in CEM cells proved difficult because this cell line expresses only 17 ,000 CD4 molecules per cell. Also, since CEM cells express the T-cell receptor-CD3 complex, which may interact with CD4, it was not clear whether an obligatory interaction of CD4 with the T-cell receptor-CD3 complex exists.
To circumvent these problems, we sought to overexpress human CD4 in Chinese hamster ovary (CHO) cells, which do not express T-cell-specific proteins. CHO cells were chosen for this study since they glycosylate proteins in a manner similar to human cells (2) (3) (4) . Furthermore, the line Pro-5 is the parental line for various glycosylation-deficient mutants (5, 6 ) that could prove useful for examining the role of glycosylation in CD4 assembly, stability, and intracellular transport. CD4 was overexpressed by cotransfecting the human multiple drug resistance (MDRJ) gene into the CHO cells and by coamplifying both transfected genes (7, 8) . After selection with colchicine, we isolated recombinant CHO cell clones that stably expressed CD4 and produced large amounts of the glycoprotein. These cell clones were then used to study the assembly and glycosylation of CD4.
MATERIALS AND METHODS Materials. Cell culture medium, fetal bovine serum, penicillin, streptomycin, and G418 were obtained from GIBCO. Cells. Human acute lymphoblastic leukemia cells (CEM-CM3) were obtained from the American Type Culture Collection and maintained as described (1) . The CHO cell lines used in this study included the parental line Pro-5 (prolinerequiring auxotroph; generic name W5, used hereafter) and the glycosylation mutants Pro-Lecl.3C (Lecl) and ProLec2.6A (Lec2). All CHO cell lines were kindly provided by Pamela Stanley (Albert Einstein College of Medicine, New York) and have been described (5) . CHO cells were cultured as a monolayer as described (9) .
Plasmids. The retroviral vector pMV7-T4 (10, 11) was a generous gift of Richard Axel (Columbia University, New York) and pHaMDR1 (7, 8) was obtained from Michael Gottesman (National Cancer Institute, Bethesda, MD). For transfections, plasmid DNA was purified by two centrifugations in cesium chloride/ethidium bromide gradients (12) .
Cell Transfection, Selection, and Cloning. CHO cells were transfected by the DNA/calcium phosphate coprecipitation technique (13) with pMV7-T4 (10 ,Ag/ml) and pHaMDR1 (4 ttg/ml). Initial selection was carried out in the neomycin analogue G418 (800 ,g/ml) and colchicine (200 ng/ml). Thereafter, the concentration of colchicine was sequentially increased by 2-fold increments up to 12.8 ,ug/ml, whereas the concentration of G418 was kept constant. The cell populations were allowed to grow for at least 14 days in each concentration ofcolchicine. Expression ofCD4 was analyzed by immunofluorescence microscopy and fluorescenceactivated cell sorting (FACS). Colonies that stained brightly in the immunofluorescence microscopy assay were cloned by replica plating (14) and subcloned by limiting dilution.
Analysis of Colchicine Resistance. The dose-response curves for colchicine resistance of CHO cell lines were determined as described (15) .
Abbreviations: FITC, fluorescein isothiocyanate; FACS, fluorescence-activated cell sorter; endo, endoglycosidase.
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DNA Isolation and Southern Blot Analysis. Genomic DNA was isolated as described (16) . The DNA was digested to completion with EcoRI, HindIII, or Xba I, ethanolprecipitated, resuspended in TE buffer (12) , and separated on a 0.6% agarose gel (12 ,4g/ml) and a2-macroglobulin (3 units/ml) were included in all reaction mixtures. Incubations were carried out in 1.5-ml Eppendorf tubes under toluene vapors at 370C for 6-16 hr.
RESULTS
The retroviral vector pMV7-T4 (10, 11) was used to transfect CHO cells-with a cDNA encoding the human CD4. To generate transfectants that express CD4 in very high amounts, a gene-linked coamplification strategy was adopted. For this purpose, a plasmid containing a full-length cDNA clone of the human gene for multiple drug resistance (MDRJ) was cotransfected into the CHO cells and amplified by sequentially subjecting the cells to increasing concentrations of colchicine in the medium (7, 8) . Cell lines that demonstrated increasing resistance to colchicine were generated by this method (Fig. 1) . To determine whether increased resistance to colchicine resulted in amplification of the CD4 DNA, genomic DNA from some of the selected cell lines was subjected to Southern blot analysis. The result demonstrated that the CD4 DNA was indeed amplified during the selection of the transfectants (Fig. 2) . To detect integration of the transfected DNA into the genome of the recipient cells, the DNA was digested with Xba I, a restriction enzyme that does not recognize the plasmid pMV7-T4. In all cell lines analyzed, the Xba I-generated fragments that hybridized with the probe were larger than 21 kilobases, indicating that integration of the transfected DNA into the genome occurred (data not shown). Expression of CD4 in the transfectants was determined by FACS and immunofluorescence microscopy at each stage of the selection. Expression of CD4 was detected after selection with colchicine (3.2 ,ug/ml) in a subpopulation of the selected cells. Single-cell clones were isolated by replica plating and limiting dilution cloning. One of the selected clones, W5C1-5-4B-77, henceforth referred to as 4B-77, was subsequently characterized in more detail. Virtually all of the cloned cells expressed CD4 when analyzed by FACS and immunofluorescence microscopy (Fig. 3 ). Significant amounts of CD4 could be immunoprecipitated from cell populations selected with colchicine (3.2 ,ug/ml), whereas in populations selected isolated, 60 ,ug of DNA was digested with EcoRl, separated on a 0.6% agarose gel, and transferred to a nylon membrane. After hybridization with a 3-kilobase EcoRl fragment isolated from pMV7-T4, which contains the coding sequence for CD4, the nylon membrane was subjected to autoradiography. Lanes: 1, DNA from the human acute lymphoblastic leukemia cell line CEM-CM3; 2, DNA from the transfectant CHO cell line W5CI-1 (cultured in colchicine at 0.2 Ag/ml); 3, DNA from W5CI-3 (cultured in colchicine at 0.8 ,.g/ml); 4 , DNA from W5CI-54B-77 (cultured in colchicine at 3.2 ,ug/ml); 5, DNA from W5CI-6 (cultured in colchicine at 6.4 ,ug/ml). Positions of DNA standards are indicated at the left in kilobases.
with higher concentrations of colchicine expression of CD4 was diminished. Cell populations resistant to colchicine concentrations as high as 12.8 ,g/ml, representing a 64-fold increase in resistance to colchicine (Fig. 1) , ceased expression of CD4, as demonstrated by immunofluorescence microscopy on permeabilized cells and by immunoprecipitation analyses of CD4 (Fig. 4) . Southern blot analysis of genomic DNA from W5C1-6 and -7 cells, which were selected with colchicine at 6.4 and 12.8 ,g/ml, respectively, failed to detect CD4 DNA (Fig. 2) . We then compared the expression of CD4 in 4B-77 cells with that in human acute lymphoblastic leukemia cells, CEM-CM3. Surface expression of CD4 was 1.9-fold higher in 4B-77 cells than in CEM cells as determined by FACS analyses, and de novo synthesis was at least 10-fold higher in 4B-77 cells than in CEM cells, as analyzed by [35S]methionine labeling and subsequent immunoprecipitation of CD4 in combination with SDS/PAGE and fluorography (data not shown). These findings as well as observations made by immunofluorescence microscopy (Fig. 3) suggested that much of the CD4 in 4B-77 resided intracellularly. By sequentially immunoprecipitating CD4 from the cell surface and the cell interior of [35S]methionine-labeled 4B-77 cells and analyzing the immunoprecipitates by SDS/PAGE and fluorography the molar ratio of intracellular to surface CD4 was estimated to be 4:1 (19) .
In the human CD4-positive cell line CEM, surface expression of CD4 depends on glycosylation of the protein. Non ofthe polypeptides of this complex, the transfected cell clone 4B-77, which does not express lymphoid-cell-specific genes except for the CD4 cDNA, was incubated with tunicamycin (0.8 ,ug/ml) for 24 hr. CD4 surface expression was decreased by 82% as compared to a 55% decrease in CEM cells after incubation with the inhibitor (20 ,g/ml). Consistent with the lack of two oligosaccharide chains in CD4 from tunicamycintreated cells was the observation that anti-CD4 antibodies immunoprecipitated a polypeptide of lower molecular weight from [35S]methionine-labeled CHO cells that were treated with tunicamycin than from untreated CHO cells (19) . Autoradiography revealed a much weaker band in precipitates from tunicamycin-treated than from control cells, suggesting that unglycosylated CD4 was rapidly degraded. These observations strongly suggest that the inhibition of surface expression of unglycosylated CD4 is independent of the cell type and of interactions with the T-cell receptor-CD3 complex. Using the same protocol for cotransfection and coamplification as described above, we transfected the cDNA for CD4 into two lectin-resistant mutants of W5, Lecl confluence in 75-cm2 flasks. After washing twice with PBS, the cells were scraped off the flask and a portion of the sample was used to determine total cellular protein content (18) . The remaining cells were lysed, the lysate was immunoprecipitated with monoclonal anti-CD4 antibody, and the immunoprecipitate was subjected to SDS/PAGE and fluorography. The bands corresponding to CD4 were excised and radioactivity was measured by liquid scintillation counting after elution of the protein with Protosol. Radioactivity associated with CD4 is expressed as cpm per 100 ,ug of total cellular protein. Molecular masses in kDa are shown to the left.
however, was much weaker on a per cell basis than in the recombinant CHO cells. CD4 could not be immunoprecipitated from untransfected control cell lines W5 and Lec2. We then determined the susceptibility of CD4 oligosaccharides to various glycosidases. Both N-Glycanase and endo F completely deglycosylated CD4 from wild-type CHO cells, whereas treatment of CD4 with sialidase or endo H did not affect the electrophoretic mobility of the glycoprotein, suggesting CD4 carries biantennary unsialylated complextype oligosaccharides. Endo H was used to study the time course of biosynthesis and assembly of CD4 by utilizing the property of glycoproteins to acquire resistance to endo H during processing in the medial Golgi. In pulse-chase studies, 4B-77 cells were labeled by a 1-min pulse of [35S]methionine followed by a chase with unlabeled methionine. CD4 was immunoprecipitated from cell lysates after various times of chase, and an aliquot of the immunoprecipitate was treated with endo H. After 20-30 min of methionine chase, CD4 became completely insensitive to endo H treatment (Fig. 5) , indicating translocation of CD4 from the endoplasmic reticulum through the Golgi and processing of the oligosaccharides of CD4 to the complex type.
DISCUSSION
We overexpressed CD4 in CHO cells to produce amounts of CD4 sufficient for analysis of the assembly and glycosylation (Fig. 2) .
Synthesis of CD4 in various transfected cell lines was quantitated by immunoprecipitation of CD4 from lysates of [35S]methionine-labeled cells (Fig. 4) . These experiments demonstrated that cells selected with concentrations of colchicine greater than 3.2 gg/ml reduced and eventually completely ceased synthesis of CD4. By immunofluorescence microscopy, we observed that in a population of transfected cells resistant to colchicine (6.4 ,ug/ml) (W5Cl-6) less than 5% of the cells were CD4-positive. Cells that did express CD4 were polynucleated syncytia, presumably resulting from the inhibition of microtubule polymerization by colchicine, whereas the CD4-negative cells were not inhibited in their ability to divide. Genomic DNA from cell populations grown at these high concentrations of colchicine did not hybridize with a CD4-specific probe in Southern blot analyses (Fig. 2) . We presume that most of the cells in this population did not retain the CD4 DNA but only the neomycin phosphotransferase gene during recombination events and that they were given a growth advantage over CD4-expressing cells. When the cell clone 4B-77 was subjected to the highest concentration of colchicine (6.4 ,ug/ml), it continued to express CD4 at high levels (Fig. 4) . The same transfection protocol was used to express CD4 in the glycosylation-deficient CHO mutant cell lines Lecl and Lec2. Only about 20% of the synthesized CD4 was actually expressed on the surface of 4B-77 cells. At present, we do not know whether this observation reflects an inability of a large proportion of CD4 molecules synthesized by 4B-77 cells to reach the cell surface or whether all molecules eventually reach the surface but only a minor fraction is expressed at the surface at any one time-i.e., whether a large recycling pool of CD4 exists intracellularly.
Biochemistry: K6nig et al.
Proc. Nati. Acad. Sci. USA 86 (1989) Treatment of CHO cells with tunicamycin at concentrations that did not affect protein biosynthesis but blocked glycosylation caused a decrease in CD4 surface expression. No intracellular accumulation of unglycosylated CD4 was observed, suggesting rapid degradation. Unglycosylated CD4 was not degraded in lysosomes but in an as yet unidentified cellular compartment; addition of lysosomal enzyme inhibitors, chloroquine or ammonium chloride, did not result in an intracellular accumulation of unglycosylated CD4 (data not shown). Nonlysosomal degradation in a pre-Golgi compartment of improperly folded and assembled proteins has been described for a viral hemagglutinin (20) and the CD3 8- chain (21), respectively. Pulse-chase labeling experiments followed by treatment of the immunoprecipitated CD4 with endo H demonstrated that the glycoprotein became insensitive to endo H treatment after 20-30 min ofmethionine chase. This observation suggests processing of the CD4 oligosaccharides in the Golgi apparatus to complex-type forms.
In this study, we showed that multiple drug resistance gene-linked coamplification is useful to overexpress the cell membrane glycoprotein CD4 in stably transfected CHO cell lines. These and other recombinant CHO cell lines can now be used to elucidate the cell biology of CD4 in more detail to understand the mechanism of degradation of unglycosylated CD4. Also, the question whether an intracellular pool of CD4 molecules constantly exchanges with surface molecules or remains unutilized may be studied in these cells. The instability of unglycosylated CD4 may have important implications for AIDS therapy in as much as soluble CD4 is currently considered as a therapeutic agent.
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